James Harold, MD
Psychiatry · Houston, TXNPI 1760543482
Payments from drug & device makers
Across 858 payments — averaging $140.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$47K
- Teva Pharmaceuticals USA, Inc.$36K
- Sunovion Pharmaceuticals Inc.$14K
- Johnson & Johnson$14K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $6K from 19 others
What the payments were for
- Consulting fees$2,4002%
- Speaking & faculty fees$92,33877%
- Travel & lodging$7,8457%
- Food & beverage$17,37614%
- Education$4650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 107 | $47,232 |
| Teva Pharmaceuticals USA, Inc. | 173 | $35,728 |
| Sunovion Pharmaceuticals Inc. | 72 | $14,483 |
| Johnson & Johnson(2 entities) | 60 | $13,754 |
| Neurocrine Biosciences, Inc. | 73 | $1,797 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,543 |
| AbbVie(2 entities) | 94 | $1,351 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,278 |
| Vanda Pharmaceuticals Inc. | 33 | $806 |
| Axsome Therapeutics, Inc. | 23 | $565 |
| Indivior Inc. | 29 | $553 |
| Lundbeck LLC | 25 | $396 |
| E.r. Squibb & Sons, L.L.C. | 10 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $227 |
| Ironshore Pharmaceuticals Inc. | 1 | $104 |
| Eisai Inc. | 4 | $71 |
| Idorsia Pharmaceuticals US Inc | 1 | $70 |
| Luye Pharma (USA) Ltd. | 2 | $41 |
| Tempus AI, Inc | 2 | $41 |
| Tris Pharma Inc | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Almatica Pharma LLC | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$92,907
- ARISTADA$89,578
- AUSTEDO$31,062
- ARISTADA INITIO$22,394
- LATUDA$13,723
- INVEGA SUSTENNA$12,160
- INVEGA TRINZA$12,160
- UZEDY$1,231
- REXULTI$383
- CAPLYTA$363
- INGREZZA$254
- Fanapt$250
- Austedo XR$235
- Auvelity$210
- SUBLOCADE$125
- COBENFY$122
- SPRAVATO$112
- Jornay PM 20mg capsules (Bottle of 100)$104
How this compares
$120,423 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 38 | $54,160 |
| Invega SustennaPaliperidone Palmitate | 14 | $50,035 |
| CaplytaLumateperone Tosylate | 13 | $21,067 |
| Lurasidone Hcl | 21 | $5,034 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 51 | $1,327 |
| Bupropion XlBupropion Hcl | 66 | $1,210 |
| Ziprasidone Hcl | 25 | $1,086 |
| Aripiprazole | 26 | $1,016 |
| Doxepin Hcl | 25 | $868 |
| Trazodone Hcl | 100 | $764 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $749 |
| Quetiapine Fumarate | 45 | $690 |
| Olanzapine | 28 | $595 |
| Gabapentin | 28 | $459 |
| Oxcarbazepine | 11 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,351 | $54,16038 claims |
| Johnson & JohnsonInvega Sustenna | $13,754 | $50,03514 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,278 | $21,06713 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $19134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.